Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . First identified during an outbreak of pneumonia in Wuhan, Hubei Province, China , it was reported to the World Health Organization (WHO) on December 31, 2019 . The virus was officially named SARS-CoV-2 in February 2020, and the disease it causes was designated COVID-19 , short for Coronavirus Disease 2019 , to avoid stigmatization.
Virology and Structure
SARS-CoV-2 is a positive-sense, single-stranded RNA virus (+ssRNA) belonging to the Coronaviridae family. It is enveloped and has one of the largest genomes among RNA viruses, ranging from 26–32 kb .
Structural Proteins
The virus contains five major structural proteins :
- Spike (S) : Facilitates entry into host cells via ACE2 and basigin (BSG/CD147) receptors.
- Envelope (E) : Involved in viral assembly and release.
- Membrane (M) : Maintains virion shape.
- Nucleocapsid (N) : Binds viral RNA genome.
- Hemagglutinin-esterase (HE) : Present in some β-coronaviruses; aids in host-cell entry.
The S protein , projecting from the viral envelope, gives the virus its characteristic “crown-like” appearance on electron microscopy and mediates host cell attachment.
Pathophysiology
SARS-CoV-2 primarily targets cells expressing ACE2 receptors , which are abundant in:
- Type II alveolar cells of the lungs
- Epithelial cells of the intestines and kidneys
- Vascular endothelium
Viral entry triggers ACE2 downregulation , potentially disrupting angiotensin homeostasis and contributing to lung injury , inflammation, and ARDS (acute respiratory distress syndrome).
Transmission
SARS-CoV-2 is primarily transmitted via:
- Respiratory droplets (>5 μm) from coughing, sneezing, or speaking
- Aerosolized particles (<5 μm), especially in enclosed spaces
- Fomite transmission (via contaminated surfaces, although less common)
- Asymptomatic and pre-symptomatic carriers
Incubation and Infectivity
- Incubation period : 2–14 days (median ~5 days)
- Infectious period : Begins ~2 days before symptom onset and lasts up to 10 days for mild cases and longer for severe cases.
- R₀ (Basic Reproduction Number) : Estimated between 2.2–3.5
Risk Factors
Individuals at higher risk of severe illness include:
- Adults >60 years old
- Individuals with comorbidities (e.g., diabetes , cardiovascular disease , chronic lung disease , cancer )
- Immunocompromised patients
- Healthcare workers exposed to high viral loads
Clinical Features
COVID-19 presents with a wide clinical spectrum, from asymptomatic to critical illness .
Common Symptoms (per CDC and WHO)
- Fever (~98%)
- Cough (~76%)
- Fatigue , malaise (~44%)
- Myalgia
- Shortness of breath
- Loss of taste or smell
- Sore throat , diarrhea , headache , and nasal congestion (less common)
Disease Severity
- 80% : Mild/asymptomatic
- 15% : Severe (requiring oxygen)
- 5% : Critical (requiring ventilation/ICU)
Complications
- Pneumonia
- ARDS
- Sepsis and septic shock
- Thromboembolic events
- Multisystem Inflammatory Syndrome (MIS-C in children)
Diagnostic Testing
Gold Standard :
- RT-PCR (real-time reverse transcription polymerase chain reaction) of nasopharyngeal swabs for viral RNA detection
Other Testing Methods :
- Antigen testing (rapid but lower sensitivity)
- Serologic (antibody) testing – indicates past exposure
- CT scan of the chest – shows bilateral ground-glass opacities in moderate to severe pneumonia
Infectious Cycle & Shedding
- Viral shedding can occur 1–2 days before symptoms appear .
- Shedding duration : 10–14 days for mild cases; longer for immunocompromised or severe cases.
- Survival on surfaces : Up to 72 hours (plastic/steel); shorter on paper, copper, or under UV exposure.
Epidemiology
As of early 2020, COVID-19 spread rapidly:
-
137,000 confirmed cases
-
5,000 deaths globally within 3 months
- Declared a pandemic by WHO on March 11, 2020
Update: As of 2025, over 770 million confirmed cases and nearly 7 million deaths have been reported globally (WHO).
Public Health Concerns and Strategies
CDC and WHO Strategies
- Non-pharmaceutical interventions (NPIs) :
- Social distancing
- Masking
- Isolation of infected individuals
- Hand hygiene
- Vaccination campaigns (from late 2020 onward)
- Global surveillance and reporting
Healthcare System Impact
- Increased hospitalization rates
- ICU strain and ventilator shortages
- Mental health challenges among healthcare workers
Prevention
- Vaccination (mRNA, viral vector, inactivated)
- Mask-wearing in high-risk settings
- Hand hygiene (≥60% alcohol-based sanitizers)
- Avoiding crowded or poorly ventilated areas
- Testing and contact tracing
Key Takeaways
| Feature | Description |
|---|---|
| Causative agent | SARS-CoV-2 |
| Transmission | Respiratory droplets, aerosols, fomites |
| Incubation period | 2–14 days (median 5 days) |
| Common symptoms | Fever, cough, fatigue, dyspnea |
| High-risk groups | Elderly, comorbid patients, healthcare workers |
| Diagnostic test | RT-PCR (gold standard) |
| Prevention | Vaccination, hygiene, masks, isolation |
| Severity distribution | 80% mild, 15% severe, 5% critical |
| Complications | ARDS, shock, thromboembolism, myocarditis, long COVID |
